Complete Genomics, Inc., a pioneering genomics company, today unveiled updated mission/vision statement to reflect renewed ambitions in taking on more for a better world, in celebration of its 18 th ...

Complete Genomics and Velsera are collaborating to deliver an end-to-end genetic testing solution that integrates DNBSEQ™ sequencing technology with Velsera’s Clinical Genomics Workspace (CGW) data ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Radoje Drmanac received a Ph.D. in molecular biology from ...

The board of Complete Genomics has recommended that its shareholders accept a $117.6 million takeover bid by China’s BGI-Shengzhen. Under terms of the agreement, a wholly owned U.S. subsidiary of ...

Complete Genomics Inc., a global life science tools leader and subsidiary of MGI Tech Co., Ltd. (“MGI”), today launched new revolutionary products and prices at Advances in Genome Biology and ...

Complete Genomics performs whole human genome sequencing using proprietary biochemistry based on DNA nanoball arrays and combinatorial probe-anchor ligation sequencing. As these methods1 produce reads ...

SAN JOSE, Calif. and MARCO ISLAND, Fla., Feb. 24, 2026 /PRNewswire/ -- Complete Genomics, a U.S.-based, innovator in genomic sequencing platforms and solutions, today announced it is commencing ...

The DNBSEQ-T1+ is a next-generation mid-throughput sequencer that completes a paired end 150 sequencing workflow in just 24 hours with Q40 accuracy. With three flow cell formats, two to four ...

SAN JOSE, Calif., June 9, 2026 /PRNewswire/ -- Complete Genomics today announced the appointment of Edward T. McMullen Jr. to its Board of Directors, further strengthening the company's leadership in ...

Complete Genomics Inc. launched a new line of genetic sequencers designed to decode DNA in greater quantities – and at a lower price point – than existing sequencing tools. The new products could ...

With confidence dropping in doing business with China-affiliated life sciences companies due to the Biosecure Act, one of the companies explicitly named in the U.S. legislation is fighting back.